PT - JOURNAL ARTICLE AU - Hirten, Robert P. AU - Danieletto, Matteo AU - Tomalin, Lewis AU - Choi, Katie Hyewon AU - Zweig, Micol AU - Golden, Eddye AU - Kaur, Sparshdeep AU - Helmus, Drew AU - Biello, Anthony AU - Pyzik, Renata AU - Nabeel, Ismail AU - Charney, Alexander AU - Glicksberg, Benjamin AU - Levin, Matthew AU - Reich, David AU - Charney, Dennis AU - Bottinger, Erwin P AU - Keefer, Laurie AU - Suarez-Farinas, Mayte AU - Nadkarni, Girish N. AU - Fayad, Zahi A. TI - Longitudinal Physiological Data from a Wearable Device Identifies SARS-CoV-2 Infection and Symptoms and Predicts COVID-19 Diagnosis AID - 10.1101/2020.11.06.20226803 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.06.20226803 4099 - http://medrxiv.org/content/early/2020/11/07/2020.11.06.20226803.short 4100 - http://medrxiv.org/content/early/2020/11/07/2020.11.06.20226803.full AB - Background Changes in autonomic nervous system function, characterized by heart rate variability (HRV), have been associated with and observed prior to the clinical identification of infection. We performed an evaluation of this metric collected by wearable devices, to identify and predict Coronavirus disease 2019 (COVID-19) and its related symptoms.Methods Health care workers in the Mount Sinai Health System were prospectively followed in an ongoing observational study using the custom Warrior Watch Study App which was downloaded to their smartphones. Participants wore an Apple Watch for the duration of the study measuring HRV throughout the follow up period. Survey’s assessing infection and symptom related questions were obtained daily.Findings Using a mixed-effect COSINOR model the mean amplitude of the circadian pattern of the standard deviation of the interbeat interval of normal sinus beats (SDNN), a HRV metric, differed between subjects with and without COVID-19 (p=0.006). The mean amplitude of this circadian pattern differed between individuals during the 7 days before and the 7 days after a COVID-19 diagnosis compared to this metric during uninfected time periods (p=0.01). Significant changes in the mean MESOR and amplitude of the circadian pattern of the SDNN was observed between the first day of reporting a COVID-19 related symptom compared to all other symptom free days (p=0.01).Interpretation Longitudinally collected HRV metrics from a commonly worn commercial wearable device (Apple Watch) can identify the diagnosis of COVID-19 and COVID-19 related symptoms. Prior to the diagnosis of COVID-19 by nasal PCR, significant changes in HRV were observed demonstrating its predictive ability to identify COVID-19 infection.Funding Support was provided by the Ehrenkranz Lab For Human Resilience, the BioMedical Engineering and Imaging Institute, The Hasso Plattner Institute for Digital Health at Mount Sinai, The Mount Sinai Clinical Intelligence Center and The Dr. Henry D. Janowitz Division of Gastroenterology.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coidisclosure.pdf and declare the following conflicts of interest: RPH discloses consulting fees from HealthMode,Inc, Janssen Pharmaceuticals, Takeda Pharmaceuticals. Research support from Intralytix Inc. and a Crohns and Colitis Foundation Career Development Award (grant number 607934). MD declares no conflicts of interest. LT declares no conflicts of interest. MZ declares no conflicts of interest. EG declares no conflicts of interest. SK declares no conflicts of interest. DH declares no conflicts of interest. AB declares no conflicts of interest. RP declares no conflicts of interest. AC declares no conflicts of interest. B.S.G. has received consulting fees from Data2Discovery, Sema4, and UCSF ML declares no conflicts of interest. IN declares no conflicts of interest. DR declares no conflicts of interest DC is co-inventor on patents filed by the Icahn School of Medicine at Mount Sinai (ISMMS) relating to the treatment for treatment-resistant depression, suicidal ideation and other disorders. ISMMS has entered into a licensing agreement with Janssen Pharmaceuticals, Inc. and it has and will receive payments from Janssen under the license agreement related to these patents for the treatment of treatment-resistant depression and suicidal ideation. Consistent with the ISMMS Faculty Handbook (the medical school policy), Dr. Charney is entitled to a portion of the payments received by the ISMMS. Since SPRAVATO has received regulatory approval for treatment-resistant depression, ISMMS and thus, through the ISMMS, Dr. Charney, will be entitled to additional payments, beyond those already received, under the license agreement. Dr. Charney is a named co-inventor on several patents filed by ISMMS for a cognitive training intervention to treat depression and related psychiatric disorders. The ISMMS has entered into a licensing agreement with Click Therapeutics, Inc. and has and will receive payments related to the use of this cognitive training intervention for the treatment of psychiatric disorders. In accordance with the ISMMS Faculty Handbook, Dr. Charney has received a portion of these payments and is entitled to a portion of any additional payments that the medical school might receive from this license with Click Therapeutics. Dr. Charney is a named co-inventor on a patent application filed by the ISMMS for the use of intranasally administered Neuropeptide Y (NPY) for the treatment of mood and anxiety disorders. This intellectual property has not been licensed. Dr. Charney is a named co-inventor on a patent application in the US, and several issued patents outside the US filed by the ISMMS related to the use of ketamine for the treatment of post-traumatic stress disorder (PTSD). This intellectual property has not been licensed. E.P. Bottinger reports consultancy agreements with Deloitte and Roland Berger; ownership interest in Digital Medicine E.Bottinger GmbH, EBCW GmbH, and Ontomics, Inc.; receiving honoraria from Bayer, Bosch Health Campus, Sanofi, and Siemens; and serving as a scientific advisor or member of Bosch Health Campus and Seer Biosciences Inc LK declares research funding from Abbvie and Pfizer, consulting for Abbvie and Pfizer, equity ownership/stock options MetaMe Health, Trellus Health MSF declares research support from Novartis and Allergenis. G.N. Nadkarni reports employment with, consultancy agreements with, and ownership interest in Pensieve Health and Renalytix AI; receiving consulting fees from AstraZeneca, BioVie, GLG Consulting, and Reata; and serving as a scientific advisor or member of Pensieve Health and Renalytix AI. ZAF discloses consulting fees from Alexion, GlaxoSmithKline and Trained Therapeutix Discovery; Research funding from Daiichi Sankyo; Amgen; Bristol Myers Squibb; Siemens Healthineers. ZAF receives financial compensation as a board member and advisor to Trained Therapeutix Discovery and owns equity in Trained Therapeutix Discovery as co-founder. Funding StatementSupport for this study was provided by the Ehrenkranz Lab For Human Resilience, the BioMedical Engineering and Imaging Institute, The Hasso Plattner Institute for Digital Health at Mount Sinai, The Mount Sinai Clinical Intelligence Center and The Dr. Henry D. Janowitz Division of Gastroenterology. There was no external funding for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB at the Icahn School of Medicine at Mount Sinai provided IRB approval for this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData collected for this study will not be made publicly available.